nach oben

Erschienen in:

01.09.2009

Interleukin 18 Promoter Variants (−137G>C and −607C>A) in Patients with Chronic Hepatitis C: Association with Treatment Response

verfasst von: Stephan L. Haas, Christel Weiß, Peter Bugert, Jutta Gundt, Heiko Witt, Manfred V. Singer, Thomas Berg, Ulrich Böcker

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Recently, two functional IL18 promoter variants, −607C>A (rs1946518) and −137G>C (rs187238), were associated with viral clearance in patients with hepatitis C. The present study focused on their relevance for treatment response.

Methods

Seven hundred fifty-seven chronically infected European patients and 791 controls were enrolled in the study. IL18 genotyping was performed by allele-specific PCR. Liver histology was available in 67.9%.

Results

Genotype and allele frequencies were equally distributed in patients and controls. No significant association with various disease characteristics was observed. However, when comparing patients with sustained virological response (SR) and non-SR, statistically significant associations were found for both variants (p = 0.0416 and p = 0.0274, respectively). In viral genotype 1, the −607A allele was positively associated with treatment response (p = 0.0190; OR 1.537; 95% CI, 1.072–2.205) and the −137G allele with a higher rate of nonresponse (p = 0.0302; OR 1.524; 95% CI, 1.040–2.233).

Conclusions

The association of IL18 variants with treatment response in genotype 1 hepatitis C patients implies a predictive and modifying role of these genetic variants.

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:35–47. doi:10.1046/j.1365-2893.1999.6120139.x

Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52. doi:10.1056/NEJM200107053450107.PubMedCrossRef

Feld JJ, Liang TJ. Hepatitis C—identifying patients with progressive liver injury. Hepatology. 2006;43:S194–206. doi:10.1002/hep. 21065.PubMedCrossRef

Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44:S19–24. doi:10.1016/j.jhep. 2005.11.009.PubMedCrossRef

Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–72. doi:10.1038/nature04082.PubMedCrossRef

Paladino N, Fainboim H, Theiler G, et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol. 2006;80:9144–50. doi:10.1128/JVI.00339-06.PubMedCrossRef

Dharel N, Kato N, Muroyama R, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res. 2006;12:4867–71. doi:10.1158/1078-0432.CCR-06-0111.PubMedCrossRef

Sartori M, Andorno S, Pagliarulo M, et al. Heterozygous beta-globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C. Gut. 2007;56:693–8. doi:10.1136/gut.2006.106641.PubMedCrossRef

Strnad P, Lienau TC, Tao GZ, et al. Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology. 2006;43:1354–63. doi:10.1002/hep.21211.PubMedCrossRef

10.

Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatol. 2005;42:846–53. doi:10.1002/hep.20860.CrossRef

11.

Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73:213–24. doi:10.1189/jlb.0602313.PubMedCrossRef

12.

Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol. 2001;19:423–74. doi:10.1146/annurev.immunol.19.1.423.PubMedCrossRef

13.

Reddy P. Interleukin-18: recent advances. Curr Opin Hematol. 2004;11:405–10. doi:10.1097/01.moh.0000141926.95319.42.PubMedCrossRef

14.

Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378:88–91. doi:10.1038/378088a0.PubMedCrossRef

15.

Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev. 2000;174:192–209. doi:10.1034/j.1600-0528.2002.017418.x.PubMedCrossRef

16.

Faggioni R, Jones-Carson J, Reed DA, et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A. 2000;97:2367–72. doi:10.1073/pnas.040561297.PubMedCrossRef

17.

Faggioni R, Cattley RC, Guo J, et al. IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol. 2001;167:5913–20.PubMed

18.

Vecchiet J, Falasca K, Cacciatore P, et al. Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann Clin Lab Sci. 2005;35:415–22.PubMed

19.

Jia HY, Du J, Zhu SH, et al. The roles of serum IL-18, IL-10, TNF-alpha and sIL-2R in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int. 2002;1:378–82.PubMed

20.

Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112:146–52. doi:10.1016/S0165-5728(00)00407-0.PubMedCrossRef

21.

Hirankarn N, Manonom C, Tangkijvanich P, Poovorawan Y. Association of interleukin-18 gene polymorphism (-607A/A genotype) with susceptibility to chronic hepatitis B virus infection. Tissue Antigens. 2007;70:160–3. doi:10.1111/j.1399-0039.2007.00865.x.PubMedCrossRef

22.

Imboden M, Nicod L, Nieters A, et al. The common G-allele of interleukin-18 single-nucleotide polymorphism is a genetic risk factor for atopic asthma. The SAPALDIA Cohort Study. Clin Exp Allergy. 2006;36:211–8. doi:10.1111/j.1365-2222.2006.02424.x.PubMedCrossRef

23.

Tiret L, Godefroy T, Lubos E, et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005;112:643–50. doi:10.1161/CIRCULATIONAHA.104.519702.PubMedCrossRef

24.

Takada T, Suzuki E, Morohashi K, Gejyo F. Association of single nucleotide polymorphisms in the IL-18 gene with sarcoidosis in a Japanese population. Tissue Antigens. 2002;60:36–42. doi:10.1034/j.1399-0039.2002.600105.x.PubMedCrossRef

25.

Bossu P, Ciaramella A, Salani F, et al. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer’s disease and correlates with cognitive impairment. Brain Behav Immun. 2008;22:487–92. doi:10.1016/j.bbi.2007.10.001.PubMedCrossRef

26.

Bossu P, Ciaramella A, Moro ML, et al. Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78:807–11. doi:10.1136/jnnp.2006.103242.PubMedCrossRef

27.

Hiromatsu Y, Mukai T, Kaku H, et al. IL-18 gene polymorphism confers susceptibility to the development of anti-GAD65 antibody in Graves’ disease. Diabet Med. 2006;23:211–5. doi:10.1111/j.1464-5491.2005.01734.x.PubMedCrossRef

28.

Sugiura T, Maeno N, Kawaguchi Y, et al. A promoter haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population. Arthritis Res Ther. 2006;8:R60. doi:10.1186/ar1930.PubMedCrossRef

29.

Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–4. doi:10.1016/0168-8278(91)90084-O.PubMedCrossRef

30.

Lloyd AR, Jagger E, Post JJ, et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol. 2007;85:24–32. doi:10.1038/sj.icb.7100010.PubMedCrossRef

31.

Oleksyk TK, Thio CL, Truelove AL, et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun. 2005;6:347–57. doi:10.1038/sj.gene.6364188.PubMedCrossRef

32.

Abbott WG, Rigopoulou E, Haigh P, et al. Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. Liver Int. 2004;24:90–7. doi:10.1111/j.1478-3231.2004.00904.x.PubMedCrossRef

33.

Minton EJ, Smillie D, Smith P, et al. Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or -10 genes. Hum Immunol. 2005;66:127–32. doi:10.1016/j.humimm.2004.11.001.PubMedCrossRef

34.

Hennig BJ, Frodsham AJ, Hellier S, et al. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int. 2007;27:1134–43. doi:10.1111/j.1478-3231.2007.01518.x.PubMedCrossRef

35.

Finotto S, Siebler J, Hausding M, et al. Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. Gut. 2004;53:392–400. doi:10.1136/gut.2003.018572.PubMedCrossRef

36.

Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol. 2002;76:10702–7. doi:10.1128/JVI.76.21.10702-10707.2002.PubMedCrossRef

37.

Fujioka N, Akazawa R, Ohashi K, Fujii M, Ikeda M, Kurimoto M. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. J Virol. 1999;73:2401–9.PubMed

38.

Tanaka-Kataoka M, Kunikata T, Takayama S, et al. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine. 1999;11:593–9. doi:10.1006/cyto.1998.0453.PubMedCrossRef

39.

Shapiro L, Puren AJ, Barton HA, et al. Interleukin 18 stimulates HIV type 1 in monocytic cells. Proc Natl Acad Sci USA. 1998;95:12550–5. doi:10.1073/pnas.95.21.12550.PubMedCrossRef

40.

Zhang PA, Wu JM, Li Y, Yang XS. Association of polymorphisms of interleukin-18 gene promoter region with chronic hepatitis B in Chinese Han population. World J Gastroenterol. 2005;11:1594–8.PubMed

41.

An P, Thio CL, Kirk GD, Donfield S, Goedert JJ, Winkler CA. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J Infect Dis. 2008;198:1159–65. doi:10.1086/592047.PubMedCrossRef

42.

Bouzgarrou N, Hassen E, Schvoerer E, et al. Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol. 2008;80:607–14. doi:10.1002/jmv.21079.PubMedCrossRef

Titel: Interleukin 18 Promoter Variants (−137G>C and −607C>A) in Patients with Chronic Hepatitis C: Association with Treatment Response
verfasst von: Stephan L. Haas
Christel Weiß
Peter Bugert
Jutta Gundt
Heiko Witt
Manfred V. Singer
Thomas Berg
Ulrich Böcker
Publikationsdatum: 01.09.2009
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 5/2009
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-009-9302-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2009

A Novel Mutation in a Patient with a Deficiency of the Eighth Component of Complement Associated with Recurrent Meningococcal Meningitis

Major Hepatectomy Induces Phenotypic Changes in Circulating Dendritic Cells and Monocytes

siRNA Knockdown of PD-L1 and PD-L2 in Monocyte-Derived Dendritic Cells only Modestly Improves Proliferative Responses to Gag by CD8+ T Cells from HIV-1-Infected Individuals

Expression of CD62L on Donor CD4+ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation

Chronic Arsenic Exposure Impairs Macrophage Functions in the Exposed Individuals